Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Vitamin K is essential for blood clotting but must be enzymatically activated. Additionally we are shipping VKORC1 Antibodies (26) and VKORC1 Proteins (4) and many more products for this protein.
Showing 4 out of 9 products:
Genetic variants of CYP2C9 (show CYP2C9 ELISA Kits)/VKORC1 and age are significant determinants of the maintenance dose of warfarin in patients with atrial fibrillation/valve replacement.
The Arg98Trp mutation disrupts an ER retention motif of VKORC1 leading to mislocalisation of the protein to outside the endoplasmatic reticulum. In this review, we summarize the clinical data, diagnosis, therapy and molecular pathomechanism of VKCFD2.
Possession of CYP2C9 (show CYP2C9 ELISA Kits)*2 and/or CYP2C9 (show CYP2C9 ELISA Kits)*3 allele variants is associated with lower time of international normalized ratio (INR (show INSR ELISA Kits)) in the therapeutic range (TTR (show TTR ELISA Kits)) values and warfarin dose variations in aortic valve replacement patients, the latter affected also by VKORC1 c.-1693G>A polymorphism
Three SNPs (CYP2C9 (show CYP2C9 ELISA Kits) *2, *3 and VKORC1 c.-1639G > A) were genotyped by electrochemical detection using a sandwich-type format that included a 3' short thiol capture probe and a 5' ferrocene-labeled signal probe.
Our results show that anticoagulated patients have a high risk of adverse events if they are carriers of 1 or more genetic polymorphisms in the VKORC1 (rs9923231) and CYP2C9 (show CYP2C9 ELISA Kits) (rs1799853 and rs1057910) genes.
The VKORC1 (-1693 G>A) AA genotype was associated with fewer cases of DVT (odds ratio = 0.435; 95% confidence interval 0.205-0.991; P = .031).
This study provides data on VKORC1 and CYP4F2 variants among an indigenous Ghanaian population. In a multivariate analysis, duration of Ghanaian patients on warfarin therapy and VKORC1 gene was associated with warfarin dose classification.
Obtained results suggested that VKORC1 -1639A allele can be a possible genetic risk factor for IS in Ukrainian population.
VKORC1-CYP2C9 (show CYP2C9 ELISA Kits) interaction can affect warfarin stable dosage.
VKORC1S1639 GG and the wild type CYP2C9 (show CYP2C9 ELISA Kits)*1*1genotypes are associated with the high-dose requirement for warfarin therapy.
quantified mRNA levels for VKORC1, VKORC1L1, GGCX (show GGCX ELISA Kits), and NQO1 (show NQO1 ELISA Kits) and measured VKOR enzymatic activities in 29 different tissues
OCN is gamma-carboxylated by the gamma-carboxylase (GGCX (show GGCX ELISA Kits)) on three glutamic acid residues, a cellular process requiring reduction of vitamin K by a second enzyme, VKORC1.
The involvement of VKORC1L1 in VKOR activity partly explains the low susceptibility of some extrahepatic tissues to vitamin K antagonists.
molecular cloning [VKORC1]
The genetic basis for resistance to anticoagulants lies in mutations in Vkorc1.
An analysis of novel mutations show that the VKORC1 gene is the main target for spontaneous mutations conferring warfarin resistance.
Each VKORC1 T-allele present in patients from the Rotterdam anticoagulation therapy study is shown to decrease the required acenocoumarol dosage by 5.1 mg/week.
Vitamin K is essential for blood clotting but must be enzymatically activated. This enzymatically activated form of vitamin K is a reduced form required for the carboxylation of glutamic acid residues in some blood-clotting proteins. The product of this gene encodes the enzyme that is responsible for reducing vitamin K 2,3-epoxide to the enzymatically activated form. Fatal bleeding can be caused by vitamin K deficiency and by the vitamin K antagonist warfarin, and it is the product of this gene that is sensitive to warfarin. In humans, mutations in this gene can be associated with deficiencies in vitamin-K-dependent clotting factors and, in humans and rats, with warfarin resistance. Two pseudogenes have been identified on chromosome 1 and the X chromosome. Two alternatively spliced transcripts encoding different isoforms have been described.
phylloquinone epoxide reductase
, vitamin K1 epoxide reductase (warfarin-sensitive)
, vitamin K epoxide reductase complex, subunit 1
, vitamin K dependent clotting factors deficiency 2
, vitamin K epoxide reductase complex subunit 1
, vitamin K1 2,3-epoxide reductase subunit 1
, Warfarin resistance